Arrowhead Pharmaceuticals director sells $173,920 in stock
A director at Arrowhead Pharmaceuticals, Adeoye Y. Olukotun, sold 2,000 shares of company stock for $173,920. The sale occurred on August 18, 2026, when the stock was trading near its 52-week high, after a significant 322% return over the past year. Despite the stock's performance, InvestingPro analysis suggests it may be overvalued.
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) reported a significant revenue increase to $829.45 million USD last year, primarily from its RNA Interference Therapeutics segment. This segment also contributed the entire $829.45 million USD from the United States market. This marks a substantial rise from the previous year's $3.55 million USD in both the segment and the US region.
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares
A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired as compensation from the issuer on December 18, 2025.
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares
Arrowhead Pharmaceuticals (NASDAQ: ARWR) director Michael Perry has filed a Form 144, indicating a proposed sale of 11,600 shares of common stock. The estimated aggregate market value of these shares is $1,012,171.97, and they were acquired as compensation in 2021, 2022, and 2025. The sale will be executed through Merrill Lynch on NASDAQ.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks
This article lists numerous ETFs that invest in Arrowhead Pharmaceuticals, Inc. stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies including mid-cap, small-cap, total market, and sector-specific approaches like healthcare and biotechnology. The purpose is to make investing in these stocks more accessible and offer diversified opportunities with lower risk.
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with 62.61% of the stock held by such investors. Despite missing analyst EPS estimates for the last quarter, Arrowhead Pharmaceuticals saw a 171% year-over-year revenue increase and maintains a "Moderate Buy" consensus rating from analysts with a target price of $97.33.
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants
Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals (ARWR). This stake includes 13,823,383 shares of Common Stock, of which 2,467,828 shares are issuable upon the exercise of warrants. The investment firm holds sole voting and dispositive power over these shares for investment purposes on behalf of Avoro Life Sciences Fund LLC.
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight
Arrowhead Pharmaceuticals (ARWR) recently reported Q3 2026 results with sales of US$75.25 million and a net loss of US$194.28 million, attracting renewed investor attention. While the stock trades close to a common fair value estimate of $89.08, a discounted cash flow model suggests a significant long-term potential with a fair value of $174.62. The company's late-stage clinical pipeline, including plozasiran, positions it for potential growth, though risks like reliance on milestone payments remain.
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Assenagon Asset Management S.A. significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 243.8% in the second quarter, bringing its total holdings to 201,927 shares valued at $16.5 million. This move is part of a broader trend where institutional investors now own 62.61% of the company. Despite a recent downgrade by Weiss Ratings, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $97.33, following a 171% revenue increase in the latest quarter even as the company reported an adjusted loss.
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals reported increased sales in Q3 2026, reaching US$75.25 million, but also experienced a widening net loss of US$194.28 million. Despite over US$400 million in year-to-date sales, the company's profitability is being impacted by rising expenses and reduced collaboration revenue. Investors are focusing on the commercial rollout and further approvals of REDEMPLO (plozasiran) as a potential offset to growing R&D and SG&A spending.
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals (ARWR) reported a significant increase in Q3 2026 sales but also saw its net loss widen considerably. Despite generating over US$400 million in year-to-date sales, rising expenses and reduced collaboration revenue are impacting profitability, making the success of their late-stage programs like REDEMPLO critical for the company's financial future. Investors are now closely scrutinizing the commercial rollout and further approvals of plozasiran as a potential offset to increasing R&D and SG&A spending.
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
Pacer Advisors Inc. has invested $1.50 million in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by purchasing 23,922 shares in the first quarter. Institutional investors now own 62.61% of the company. Despite reporting a quarterly revenue beat, Arrowhead Pharmaceuticals missed EPS expectations, leading to some reduced future EPS forecasts by analysts, though the overall sentiment remains a "Moderate Buy" with an average price target of $97.33.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average recommendation of "Moderate Buy" from thirteen brokerages, with an average 12-month price target of $97.33. Analysts have mixed outlooks, with some raising price targets and long-term EPS forecasts, while others cut near-term earnings estimates, reflecting expected losses through fiscal 2027. Despite significant revenue growth in its latest quarter, the company missed EPS expectations, reporting a larger loss than anticipated.
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress
Arrowhead Pharmaceuticals (ARWR) stock dropped 3% after reporting a widening net loss of US$194.3m in Q3 2026, despite increased revenue and positive Phase III trial results for plozasiran. The market reacted to the deepening losses, while long-term investors are likely weighing the R&D spend against the significant drug development progress. The company faces challenges with heavy cash burn and reliance on partner funding, though its late-stage pipeline is expanding.
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside
Arrowhead Pharmaceuticals, Inc. (ARWR) has seen its average 12-month price target raised from $107.6 to $110.2 by 10 analysts, suggesting a 23% potential upside from its August 4th closing price. The consensus rating for the stock remains a "Buy" among 14 covering analysts, with 13 recommending a Buy and one a Hold.
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review process for its upcoming Supplemental New Drug Application (sNDA) for plozasiran. This sNDA aims to expand the approved indication of plozasiran, currently marketed as REDEMPLO, to include patients with severe hypertriglyceridemia (sHTG). The priority review designation is expected to reduce the FDA's review time from 10 months to six months, helping to bring this important medicine to patients with sHTG more quickly.
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals reported its Q3 2026 earnings, highlighting positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG) and an acceleration of its supplemental New Drug Application. The company also saw significant growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS) and outlined upcoming pipeline readouts. Despite a net loss, revenue increased, and the company maintains a strong financial position with $1.6 billion in cash and investments.
FDA voucher could put Arrowhead's planned drug filing on a six-month review track
Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this voucher to expedite the FDA review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at treating severe hypertriglyceridemia (sHTG), potentially shortening the review period to six months. This move follows positive Phase 3 clinical study results and is intended to accelerate market access for the important new medicine.
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), leading to plans for a supplemental New Drug Application. The company also highlighted continued growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS), with prescription volumes more than doubling. Despite a net loss of $194.3 million in Q3, revenue increased significantly due to collaboration agreements and REDEMPLO sales, and the company maintains a strong financial position with $1.6 billion in cash and investments.
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals announced its fiscal 2026 third-quarter results, highlighting significant progress in its commercial product REDEMPLO and its robust R&D pipeline. Key achievements include the strong momentum of REDEMPLO's U.S. launch and new marketing authorizations in Europe and Australia, positive topline results for plozasiran in severe hypertriglyceridemia, and advancements in other clinical programs. The company also acquired a priority review voucher for plozasiran and entered into a significant licensing agreement for ARO-PNPLA3.
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this PRV to accelerate the review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at expanding its approved indication to include patients with severe hypertriglyceridemia (sHTG). This acquisition could shorten the FDA review process for plozasiran from 10 to six months, highlighting its potential to transform treatment for sHTG patients.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 3, 2026
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, fall under NASDAQ Listing Rule 5635(c)(4) and are separate from stockholder-approved equity incentive plans, vesting annually over four years. Arrowhead Pharmaceuticals is a commercial-stage pharmaceutical company focused on developing RNAi therapeutics to treat intractable diseases.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors approved inducement grants to 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, are made under NASDAQ Listing Rule 5635(c)(4) and vest annually over four years, operating outside the company's existing equity incentive plans. The company specializes in developing RNAi therapeutics for various intractable diseases.
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone
Arrowhead Pharmaceuticals announced positive Phase 3 results for plozasiran in severe hypertriglyceridemia and completed enrollment for the zodasiran Phase 3 trial. These developments bolster the company's cardiometabolic RNAi pipeline, potentially diversifying future revenue and broadening treatment options for lipid disorders. The strong clinical data may positively impact Arrowhead's investment narrative and risk profile, especially as earlier analyst estimates were more pessimistic.
Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake
Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power over 33,548 shares and sole dispositive power over all 6.38 million shares. The filing clarifies that no single individual investor within Vanguard's managed accounts holds more than 5% of Arrowhead's common stock.
B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123
B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.
Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress
Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk and opportunity mix. While a discounted cash flow model suggests the stock is heavily undervalued, the narrative relies on revenue growth, margin expansion, and successful trial progression, making it sensitive to potential setbacks.
Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Arrowhead Pharmaceuticals (ARWR) had 801 employees worldwide as of March 2026, marking a 51.4% growth since 2023. The company is actively hiring, with 152 active job postings in 2026, and its workforce is primarily concentrated in the United States. Revelio Labs data indicates that the average salary is $135,729 and employee sentiment is neutral but improving.
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside
Arrowhead Pharmaceuticals, Inc.'s stock 12-month price target has been increased from $104.7 to $105.4 by analysts, indicating a potential 23% upside from its July 27th closing price. The consensus rating from 14 analysts remains a "Buy," with a range of forecasts from $87 to $126 per share.
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNAi therapeutic targeting homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, after which Arrowhead plans to seek regulatory approval. Zodasiran works by reducing ANGPTL3 expression to lower atherogenic lipoproteins, offering a new treatment approach for this rare genetic condition that causes severely elevated LDL-C and early-onset cardiovascular disease.
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial
Arrowhead Pharmaceuticals announced the completion of enrollment for its Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNA interference treatment for homozygous familial hypercholesterolemia (HoFH). While this is a significant milestone, the company's financial metrics reflect challenges in profitability and growth, with a GF Score of 49 and recent insider selling activity. Investors are advised to consider both the clinical progress and financial performance when evaluating ARWR stock.
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients
Arrowhead Pharmaceuticals announced the completion of enrollment for its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA interference therapeutic for homozygous familial hypercholesterolemia (HoFH). The study, which initially aimed for 60 participants but enrolled 70 due to strong interest, is expected to conclude in mid-2027, after which Arrowhead plans to seek regulatory approval. Zodasiran targets ANGPTL3 to lower atherogenic lipoproteins, offering a new mechanism for treating this rare genetic condition that causes severely elevated LDL-C and early cardiovascular disease.
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNA interference therapeutic for homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, with regulatory approval sought thereafter. Zodasiran aims to lower atherogenic lipoproteins by reducing ANGPTL3 expression, targeting a significant unmet need in patients with exceptionally high cardiovascular risk due to HoFH.
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1
Arrowhead Pharmaceuticals, Inc. generated 660.65 million CHF in revenue last year, primarily from its RNA Interference Therapeutics segment. This marks a significant increase from 3.01 million CHF in the previous year. The United States was the largest contributor to the company's revenue.
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1
Arrowhead Pharmaceuticals Inc. (XETR:HDP1) reported a total revenue of €706.85 million last year, primarily driven by its RNA Interference Therapeutics segment. The United States was the leading geographical contributor, generating the entirety of this revenue. This marks a significant increase from €3.19 million in the previous year.
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
Arrowhead Pharmaceuticals (ARWR) has transitioned into a commercial company with its first approved drug, REDEMPLO, and a strong pipeline. While the stock has seen significant growth and has a high valuation, indicating market belief in future potential, its history shows high volatility and deep drawdowns during market downturns. Investors must weigh the company's successful drug launch and clinical trial results against its elevated price and the need for continued commercial execution.
Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos
Arrowhead Pharmaceuticals (ARWR) reached a new 52-week high after reporting successful late-stage trial results for its lipid-lowering drug, plozasiran, which showed an 81% median triglyceride reduction. Despite the positive news and a significant market cap of $13.02 billion, the company holds a low GF Score™ of 45/100, indicating potential weaknesses in profitability and growth. Additionally, insiders have sold $1.9 million worth of shares in the last three months, suggesting caution alongside the promising drug developments.
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?
Arrowhead Pharmaceuticals Inc. (ARWR) stock rose 19.04% on July 22, driven by positive Phase 3 clinical trial results for its RNA interference candidate in cardiometabolic disorders. Despite the strong fundamental news and analyst price target increases, technical indicators like MACD and Williams %R suggest sell conditions. The article also notes company-specific risks such as significant equity dilution and high operational cash burn.
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat
Arrowhead Pharmaceuticals' (NASDAQ: ARWR) drug plozasiran has shown strong efficacy in reducing triglyceride levels and acute pancreatitis occurrences in patients with severe hypertriglyceridemia across two Phase 3 trials, SHASTA-3 and SHASTA-4. Patients receiving 25 mg quarterly saw significant reductions in triglyceride levels, and high-risk patients experienced a 100% reduction in pancreatitis incidents. The drug demonstrated a favorable safety profile, and the company plans to submit a supplemental new drug application to the U.S. FDA by the end of 2026.
Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run
Arrowhead Pharmaceuticals has seen an extreme 398.1% gain over the past year, leading to a valuation that is now considered fairly priced rather than an obvious bargain. While the recent European Commission authorization for Redemplo supports higher revenue expectations, clinical and reimbursement uncertainties for its rare condition treatment familial chylomicronemia syndrome remain a risk. The company's P/S ratio of 16.9x is above the biotech industry average, but its "Fair Ratio" is 15.7x, suggesting it's close to fair value given growth, margins, and risk.
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals announced positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran for severe hypertriglyceridemia (sHTG). The drug achieved deep and consistent triglyceride reductions of 79% and 81%, respectively, and statistically significant reductions in acute pancreatitis events, including a 100% reduction in high-risk patients. These findings support Arrowhead's plan to seek regulatory approval globally, with an sNDA filing in the U.S. before the end of the year.
Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight
Arrowhead Pharmaceuticals (ARWR) surged 24.4% to $92.72 after JP Morgan upgraded the biotech's rating to Overweight and raised its price target from $88 to $95. This upgrade was attributed to positive regulatory signals from the FDA, energizing investor interest in the RNAi therapeutics developer. The move reflects renewed optimism in the company's prospects as it advances its pipeline, and investors are advised to watch for further FDA announcements or clinical trial readouts.
ARWR Jumps As REDEMPLO Win Fuels Bullish Targets
Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 22% after European regulators approved its drug REDEMPLO for familial chylomicronemia syndrome, backed by strong Phase 3 data. This approval, combined with bullish analyst targets from Stifel and JPMorgan anticipating a $3B market for upcoming severe hypertriglyceridemia data, is driving significant investor optimism. The company is now eyed for its potential in a new phase of growth, with upcoming Q3 2026 results on August 4, 2026, offering a checkpoint on its financial execution.
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug
Arrowhead Pharmaceuticals announced positive late-stage trial results for its lipid-lowering drug, plozasiran, intended for patients with severe hypertriglyceridemia. This news negatively impacted Ionis Pharmaceuticals, a competitor in the same therapeutic area. An earlier version of the story was corrected to reflect that Ionis Pharma's sHTG drug had already received FDA approval in June.
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw its shares jump 18% after announcing positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials for plozasiran. The trials successfully met all primary and secondary endpoints, showing significant reductions in triglyceride levels and a favorable safety profile compared to placebo. The company plans to submit a supplemental New Drug Application to the FDA for severe hypertriglyceridemia by the end of 2026.
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter, which ended on June 30, 2026. Investors can access the live audio webcast on the company's website, with a replay available two hours after the call. Analysts wishing to participate in the conference call can register online to receive dial-in details and a personalized PIN.
Press Release: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will webcast its fiscal 2026 third-quarter results. The conference call is scheduled for August 7, 2026, at 4:30 p.m. ET. Investors can access the webcast and replay on the company's website.
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals announced it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter, which ended June 30, 2026. Investors can access the live audio webcast and its replay on the company's website, while analysts need to register online to participate in the conference call. Arrowhead Pharmaceuticals is a commercial-stage company focused on developing RNA interference (RNAi) therapeutics for intractable diseases.
Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?
Arrowhead Pharmaceuticals (ARWR) is attracting investor attention, with a recent 4.1% share price increase after an 8.3% monthly drop. While the company is considered 16.6% undervalued with a fair value of $89.08 based on its late-stage clinical pipeline, its P/S ratio of 16.8x is above the industry average, suggesting potential overvaluation in some metrics. Investors are advised to weigh the potential rewards from its pipeline against the risks of high R&D spending and the need for successful trial results.
ARWR6277444 Bond Risk Profile
This article provides a risk profile for the Arrowhead Pharmaceuticals, Inc. bond ARWR6277444, maturing on January 15, 2032. It highlights key metrics for credit risk assessment, including security level and issuer rating. The profile also mentions the availability of exclusive analyst ratings for bonds.
